Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies - PubMed (original) (raw)
. 2020 Jan 1;126(9):1905-1916.
doi: 10.1002/cncr.32776. Epub 2020 Feb 25.
Jung Julie Kang 1, Anna Lee 1, Dan Fan 1, Huili Wang 1, Sarin Kitpanit 1, Pamela Fox 3, Kevin Sine 3, Dennis Mah 3, Sean M McBride 1, Chiaojung Jillian Tsai 1, Nadeem Riaz 1, Lara A Dunn 4, Eric J Sherman 4, Loren Michel 4, Bhuvanesh Singh 5, Ian Ganly 5, Richard J Wong 5, Jay O Boyle 5, Marc A Cohen 5, Nancy Y Lee 1
Affiliations
- PMID: 32097507
- PMCID: PMC7304541
- DOI: 10.1002/cncr.32776
Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies
Ming Fan et al. Cancer. 2020.
Abstract
Background: Proton therapy (PT) improves outcomes in patients with nasal cavity (NC) and paranasal sinus (PNS) cancers. Herein, the authors have reported to their knowledge the largest series to date using intensity-modulated proton therapy (IMPT) in the treatment of these patients.
Methods: Between 2013 and 2018, a total of 86 consecutive patients (68 of whom were radiation-naive and 18 of whom were reirradiated) received PT to median doses of 70 grays and 67 grays relative biological effectiveness, respectively. Approximately 53% received IMPT.
Results: The median follow-up was 23.4 months (range, 1.7-69.3 months) for all patients and 28.1 months (range, 2.3-69.3 months) for surviving patients. The 2-year local control (LC), distant control, disease-free survival, and overall survival rates were 83%, 84%, 74%, and 81%, respectively, for radiation-naive patients and 77%, 80%, 54%, and 66%, respectively for reirradiated patients. Among radiation-naive patients, when compared with 3-dimensional conformal proton technique, IMPT significantly improved LC (91% vs 72%; P < .01) and independently predicted LC (hazard ratio, 0.14; P = .01). Sixteen radiation-naive patients (24%) experienced acute grade 3 toxicities; 4 (6%) experienced late grade 3 toxicities (osteoradionecrosis, vision loss, soft-tissue necrosis, and soft tissue fibrosis) (grading was performed according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 5.0]). Slightly inferior LC was noted for patients undergoing reirradiation with higher complications: 11% experienced late grade 3 toxicities (facial pain and brain necrosis). Patients treated with reirradiation had more grade 1 to 2 radionecrosis than radiation-naive patients (brain: 33% vs 7% and osteoradionecrosis: 17% vs 3%).
Conclusions: PT achieved remarkable LC for patients with nasal cavity and paranasal sinus cancers with lower grade 3 toxicities relative to historical reports. IMPT has the potential to improve the therapeutic ratio in these malignancies and is worthy of further investigation.
Keywords: nasal cavity; paranasal sinus; pencil beam proton therapy; radiotherapy; reirradiation; toxicity.
© 2020 American Cancer Society.
Conflict of interest statement
Conflict of interests: None
Figures
Figure 1.
Consort diagram
Figure 2.
LC with IMPT vs. 3DCPT in RT-naïve patients.
Figure 3.
A 45-year old male diagnosed with an unresectable T4bN0M0 sphenoid sinus adenoid cystic carcinoma. There was significant temporal lobe invasion of this tumor. An IMPT plan (sagittal, axial, and coronal views) delivered using pencil beam scanning technique with a total dose of 76CGE (Figure 3A). Red isodose line encompassed the GTV (pre-treatment MRI in figure B shows clearly this tumor). The patient had complete response and is currently NED for 34 months but has developed Grade 2 temporal lobe necrosis gradually getting worse over time (Figure B): Representative T1 post MRI scans, pre-proton (upper left row ), 6 months post-proton (upper right row), 20 months post-proton (lower left row), and 32 months post-proton (lower right row). The serial MRI scans clearly show resolution of tumor and enlarging temporal lobe necrosis over time directly situated in the prior gross tumor volume (Figure 3B).
Similar articles
- Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China.
Li G, Qiu B, Huang YX, Doyen J, Bondiau PY, Benezery K, Xia YF, Qian CN. Li G, et al. BMC Cancer. 2020 Jun 26;20(1):599. doi: 10.1186/s12885-020-07083-x. BMC Cancer. 2020. PMID: 32590957 Free PMC article. - Postoperative intensity-modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: technique, early outcomes, and toxicity.
Hoppe BS, Wolden SL, Zelefsky MJ, Mechalakos JG, Shah JP, Kraus DH, Lee N. Hoppe BS, et al. Head Neck. 2008 Jul;30(7):925-32. doi: 10.1002/hed.20800. Head Neck. 2008. PMID: 18302261 - Long-Term Outcomes After Proton Beam Therapy for Sinonasal Squamous Cell Carcinoma.
Russo AL, Adams JA, Weyman EA, Busse PM, Goldberg SI, Varvares M, Deschler DD, Lin DT, Delaney TF, Chan AW. Russo AL, et al. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):368-376. doi: 10.1016/j.ijrobp.2016.02.042. Epub 2016 Feb 18. Int J Radiat Oncol Biol Phys. 2016. PMID: 27084654 - Carbon ion radiation therapy for sinonasal malignancies: Promising results from 2282 cases from the real world.
Zhang W, Hu W, Hu J, Gao J, Yang J, Kong L, Lu JJ. Zhang W, et al. Cancer Sci. 2020 Dec;111(12):4465-4479. doi: 10.1111/cas.14650. Epub 2020 Oct 16. Cancer Sci. 2020. PMID: 32936975 Free PMC article. - Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis.
Patel SH, Wang Z, Wong WW, Murad MH, Buckey CR, Mohammed K, Alahdab F, Altayar O, Nabhan M, Schild SE, Foote RL. Patel SH, et al. Lancet Oncol. 2014 Aug;15(9):1027-38. doi: 10.1016/S1470-2045(14)70268-2. Epub 2014 Jun 26. Lancet Oncol. 2014. PMID: 24980873 Review.
Cited by
- Radiation therapy strategies for skull-base malignancies.
Palmer JD, Gamez ME, Ranta K, Ruiz-Garcia H, Peterson JL, Blakaj DM, Prevedello D, Carrau R, Mahajan A, Chaichana KL, Trifiletti DM. Palmer JD, et al. J Neurooncol. 2020 Dec;150(3):445-462. doi: 10.1007/s11060-020-03569-7. Epub 2020 Aug 12. J Neurooncol. 2020. PMID: 32785868 Review. - Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Li X, Kitpanit S, Lee A, Mah D, Sine K, Sherman EJ, Dunn LA, Michel LS, Fetten J, Zakeri K, Yu Y, Chen L, Kang JJ, Gelblum DY, McBride SM, Tsai CJ, Riaz N, Lee NY. Li X, et al. JAMA Netw Open. 2021 Jun 1;4(6):e2113205. doi: 10.1001/jamanetworkopen.2021.13205. JAMA Netw Open. 2021. PMID: 34143193 Free PMC article. - Metastatic patterns and treatment options for head and neck cutaneous squamous cell carcinoma (Review).
Iancu D, Fulga A, Vesa D, Zenovia A, Fulga I, Sarbu MI, Tatu AL. Iancu D, et al. Mol Clin Oncol. 2024 Apr 24;20(6):40. doi: 10.3892/mco.2024.2739. eCollection 2024 Jun. Mol Clin Oncol. 2024. PMID: 38756868 Free PMC article. Review. - The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer.
Kang JJ, Wong RJ, Sherman EJ, Rybkin A, McBride SM, Riaz N, Tsai CJ, Yu Y, Chen L, Zakeri K, Gelblum DY, Gillespie EF, Cohen MA, Cracchiolo JR, Ganly I, Patel S, Singh B, Boyle JO, Roman BR, Morris LG, Shaha AR, Dunn LA, Ho AL, Fetten JV, Shah JP, Pfister DG, Lee NY. Kang JJ, et al. Cancer. 2020 Sep 15;126(18):4092-4104. doi: 10.1002/cncr.33031. Epub 2020 Jul 8. Cancer. 2020. PMID: 32639615 Free PMC article. - A Patient Selection Approach Based on NTCP Models and DVH Parameters for Definitive Proton Therapy in Locally Advanced Sinonasal Cancer Patients.
Mirandola A, Russo S, Bonora M, Vischioni B, Camarda AM, Ingargiola R, Molinelli S, Ronchi S, Rossi E, Vai A, Iacovelli NA, Thariat J, Ciocca M, Orlandi E. Mirandola A, et al. Cancers (Basel). 2022 May 28;14(11):2678. doi: 10.3390/cancers14112678. Cancers (Basel). 2022. PMID: 35681661 Free PMC article.
References
- Turner JH and Reh DD Incidence and survival in patients with sinonasal cancer: A historical analysis of population‐based data. Head Neck, 2012;34: 877–885. - PubMed
- Ganly I, Patel SG, Singh B, et al. Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study. Head Neck. 2005;27:575–84. - PubMed
- Patel SG, Singh B, Polluri A, Bridger PG, Cantu G, Cheesman AD, deSa GM, Donald P, Fliss D, Gullane P, Janecka I, Kamata SE, Kowalski LP, Kraus DH, Levine PA, dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP. Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. Cancer. 2003;98:1179–87. - PubMed
- National Comprehensive Cancer Network. Head and Neck Cancer (Version 3.2019). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed September 1, 2019.
- Robbins KT, Ferlito A, Silver CE, et al. Contemporary management of sinonasal cancer. Head Neck. 2011;33:1352–65. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical